La cadena de opciones muestra datos clave de las opciones de acciones de Estrella Immunopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Estrella Immunopharma..

Estrella Immunopharma (NASDAQ:ESLA) Bolsa, Cadena de Opciones

Estrella Immunopharma

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma Inc

Global investment manager&nbsp;Van Eck&nbsp;has reiterated its <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984505/bitcoin-to-peak-at-180000-says-vanecks-head-of-digital-assets-research">ambitious&nbsp;$180,000 price target</a> for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), projecting this peak within the current market cycle.
What Happened: VanEck analysts&nbsp;Nathan Frankovitz&nbsp;and&nbsp;Matthe Sigel <a href="https://www.vaneck.com/us/en/blogs/digital-assets/matthew-sigel-vaneck-mid-november-bitcoin-chaincheck">suggest</a> that favorable regulatory developments in the U.S. and increased institutional interest could propel Bitcoin to this target within 18 months.
The analysts attribute the recent surge in Bitcoin&#8217;s price, which touched $99,800 in the last 24&nbsp;hours, to the election victory of&nbsp;Donald Trump.
The analysts noted that Bitcoin entered a &#8220;new phase&#8221; on Nov. 11, with perpetual futures contracts&#8217; funding rates surpassing 10%, indicating short- to medium-term momentum.
"This shift points toward stronger short- to medium-term momentum, as historically, elevated funding rates have been linked to higher 30 to 90-day returns, reflecting heightened bullish sentiment and demand."
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42097462/dogecoin-millionaire-shares-50-million-meme-coin-strategy-for-2025-pepe-brett-are-this-bull-runs-doge-shiba-inu?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Millionaire&#8217; Shares $50 Million Meme Coin Strategy For 2025: Pepe, Brett Are This Bull Run&#8217;s DOGE, Shiba Inu</a>
However, they cautioned that sustained high funding rates could deter investors seeking long-term returns.
"On average, purchases made on days when funding rates were above 10% began underperforming at the 180-day mark, with this trend becoming even more pronounced over 1-year and 2-year periods."
Why It Matters: The bullish sentiment from Van Eck comes amid a broader context of market dynamics and expert predictions.
Mike Novogratz, CEO of Galaxy Digital Holdings Ltd., <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">recently warned about the high levels of leverage</a> in the crypto market, suggesting that while Bitcoin&#8217;s rise to $100,000 seems inevitable, a correction to $80,000 could occur due to excessive leverage.
Furthermore,&nbsp;Michaël van de Poppe, a leading cryptocurrency analyst, has forecasted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">multiple flash crashes for Bitcoin</a> before the year ends, potentially dropping its value by 5-10% in a single day. These corrections, however, could present strategic entry points for investors, as altcoins might experience significant growth post-correction.
Additionally, Van Eck&#8217;s CEO,&nbsp;Jan van Eck, has previously expressed a bold prediction that Bitcoin could <a href="https://www.benzinga.com/24/11/42009965/vaneck-ceo-boldly-predicts-bitcoin-at-300k-per-coin-reaching-half-of-golds-market-cap-in-the-face-of-growing-demand">eventually reach $300,000</a>, capturing a substantial share of the gold market as a digital alternative. This long-term outlook underscores the growing demand and institutional interest in Bitcoin as a hedge against inflation.
Price Action: At the time of writing, Bitcoin was trading at $98,663, down by 0.76% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098871/bitcoin-holding-on-to-94000-ethereum-dogecoin-trade-lower-place-your-bets-up-or-down-brothers-says-trader?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Holding On To $94,000, Ethereum, Dogecoin Trade Lower: &#8216;Place Your Bets, Up Or Down Brothers&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Price Target

Markets

$BTC

Bitcoin Could Reach $180K In Current Cycle Thanks To Trump Victory, Says VanEck, But Has This Warning For Investors

Bankrupt cryptocurrency exchange&nbsp;FTX has announced plans to begin distributing payments to creditors and customers in early 2025. This follows the approval of its&nbsp;Chapter 11 Plan of Reorganization, which is expected to become effective by January.
What Happened:&nbsp;John Jay Ray III, the CEO of FTX, announced that the company anticipates its&nbsp;Chapter 11 Plan of Reorganization&nbsp;will be effective by January 2025.
Ray expressed satisfaction with the progress, stating, &#8220;We&nbsp;are pleased to announce that&nbsp;we will begin distributing proceeds&nbsp;in early 2025.&#8221;
He emphasized the expertise and ongoing efforts of the professional team supporting the debtors, who have already recovered billions for FTX&#8217;s creditors and customers.
See Also:&nbsp;<a href="https://www.benzinga.com/general/education/24/11/42098422/heres-how-much-100-invested-in-cardano-today-could-be-worth-if-ada-hits-new-all-time-highs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Here&#8217;s How Much $100 Invested In Cardano Today Could Be Worth If ADA Hits New All-Time Highs</a>
The announcement follows FTX&#8217;s nearing completion of the final steps required for the reorganization plan.
Payments are expected to be made within 60 days of the plan&#8217;s activation.
&#8220;While&nbsp;we continue to take actions&nbsp;to maximize recoveries, we are&nbsp;full steam ahead to reach&nbsp;arrangements with our distribution agents&nbsp;and return proceeds to creditors&nbsp;and customers as quickly as&nbsp;possible," Ray added.
FTX plans to finalize arrangements&nbsp;with specialized distribution agents by&nbsp;early December. These agents will&nbsp;facilitate the global distribution of recoveries to customers, who will receive instructions to establish approved accounts with these agents.
FTX aims to announce the exact&nbsp;effective date of distribution by&nbsp;the end of next month.
Why It Matters: The announcement marks a pivotal moment in FTX&#8217;s bankruptcy proceedings.
In October, a U.S. bankruptcy judge approved&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41234936/ftx-to-repay-creditors-up-to-16-5b-is-this-bullish-for-bitcoin">FTX's plan</a>&nbsp;to repay creditors up to $16.5 billion, concluding a two-year bankruptcy saga.
This decision came after a series of legal challenges, including a&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40248878/ftx-alameda-ordered-to-pay-12-7b-to-creditors-by-u-s-judge">$12.7 billion restitution order</a>&nbsp;in August and a settlement over&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40791711/ftx-moves-to-settle-600m-robinhood-shares-dispute-with-14m-payment-amid-bankruptcy-proceed">Robinhood shares</a>&nbsp;in September.
The approval of the reorganization plan and the upcoming payments are crucial for restoring trust in the crypto ecosystem and providing relief to affected creditors and customers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42125642/bitcoin-ethereum-dogecoin-prepping-for-an-early-thanksgiving-btc-is-currently-less-than-one-eth-away-from-100000-says-trader?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Prep For Early Thanksgiving: &#8216;BTC Is Currently (Less Than) One ETH Away From $100,000, Says Trader</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Bankrupt Crypto Exchange FTX To Commence Payments To Customers, Creditors In Early 2025

In a significant development for lunar exploration, Elon Musk-led&nbsp;SpaceX&#8216;s <a href="https://www.benzinga.com/topic/starship">Starship</a> has been chosen by&nbsp;Lunar Outpost&nbsp;to deliver its new moon rover, Eagle, to the lunar surface.
What Happened: This comes after a successful suborbital test flight of the 400-foot-tall Starship from Texas, marking its sixth flight.
&#8220;Having experienced the recent groundbreaking&nbsp;Starship test flight firsthand, we&#8217;re&nbsp;confident that SpaceX is advancing&nbsp;the most capable launch system&nbsp;ever created and will successfully&nbsp;land our Eagle vehicles on&nbsp;the surface of the moon," said Justin Cyrus, founder and CEO of Lunar Outpost.
This contract is a crucial step for Lunar Outpost&#8217;s mission to establish&nbsp;a sustainable human presence in&nbsp;space.
The company is collaborating with Leidos, MDA Space, Goodyear, and General Motors on the Eagle Rover.
The &#8220;Lunar Dawn&#8221; team, including Lunar Outpost, is one of three private groups selected by NASA to develop a version of the Lunar Terrain Vehicle (LTV) for the Artemis program.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42081589/tesla-electric-offers-unlimited-overnight-charging-for-just-5-a-month-as-ev-giant-races-toward-500k-sales-target?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Electric Offers Unlimited Overnight Charging For Just $5 A Month As EV Giant Races Toward 500K Sales Target</a>
SpaceX&#8217;s Starship is also set to launch another LTV rover, FLEX, developed by&nbsp;Venturi Astrolab.
NASA has chosen Starship for its first crewed lunar landing under the <a href="https://www.benzinga.com/news/24/10/41400036/nasa-assigns-2-missions-to-spacex-for-2025-after-boeings-starliner-stranded-astronauts">Artemis 3 mission</a>, scheduled for late 2026.
Why It Matters: The selection of SpaceX&#8217;s Starship for the lunar mission underscores the company&#8217;s growing role in space exploration.
Recently, <a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs">SpaceX unveiled a conceptual image</a> of the Starship Human Landing System (HLS) designed to facilitate the first human landing on the Moon since 1971.
This version of Starship will feature landing legs instead of a heat shield and flaps.
Additionally, Musk has expressed confidence in <a href="https://www.benzinga.com/general/space/24/11/42082169/elon-musk-predicts-tesla-cybertrucks-optimus-robots-will-be-aboard-spacex-starships-to-mars-in-2-years">SpaceX&#8217;s ability to send uncrewed Starships to Mars</a> within two years, potentially carrying&nbsp;Tesla Inc.&nbsp;Cybertrucks and Optimus robots as payloads.
Meanwhile,&nbsp;SpaceX&#8217;s satellite internet division, Starlink, <a href="https://www.benzinga.com/24/11/42082877/spacexs-starlink-enables-realtime-views-of-earth-during-starships-6th-test-flight-could-it-be-the-future-of-space-connectivity">demonstrated real-time Earth views</a> during Starship&#8217;s sixth test flight, showcasing the potential for enhanced space connectivity.
While SpaceX is currently a privately held company, investors can leverage&nbsp;Destiny Tech100 Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) to participate in the Musk-led space company&#8217;s growth. According to data from&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, DXYZ has gained over 366% year-to-date.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: SpaceX

SPACE

Tech

DXYZ

Elon Musk's SpaceX Secures New Moon Mission Contract After Starship's Successful 6th Test Flight

Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)&nbsp;is gearing up to introduce its budget-friendly ID.2 electric vehicle by the end of 2025, with an SUV version to follow. This move marks a significant step in Volkswagen&#8217;s strategy to expand its electric vehicle lineup.
What Happened: Volkswagen&nbsp;is on schedule to release its budget-friendly ID.2 electric vehicle by late 2025, <a href="https://www.autocar.co.uk/car-news/new-cars/volkswagen-overhaul-entire-electric-car-line-up-2026">reported</a> Autocar. This model is expected to be the most economical in the company&#8217;s lineup, priced under $27,000 (€25,000).
At the LA Auto Show,&nbsp;Volkswagen&#8217;s tech development head,&nbsp;Kai Grünitz, confirmed that the ID.2 will lead a major overhaul of the brand&#8217;s &#8220;ID&#8221; electric car series. Grünitz indicated that significant advancements are anticipated,&nbsp;starting in 2026, with a&nbsp;fresh design approach.
"It's matching 100% to our brand values: it will be stable and likable with our secret sauce—but in a different way," Grünitz said, according to the report.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42081589/tesla-electric-offers-unlimited-overnight-charging-for-just-5-a-month-as-ev-giant-races-toward-500k-sales-target?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Electric Offers Unlimited Overnight Charging For Just $5 A Month As EV Giant Races Toward 500K Sales Target</a>
The&nbsp;ID.2 will be the first&nbsp;vehicle to utilize&nbsp;Volkswagen&#8217;s new MEB Entry Platform. An SUV version is slated for a reveal&nbsp;at the Munich Motor Show&nbsp;in September 2025, with a GTI model also in development.
Grünitz emphasized that the ID.2 will mark a new beginning for&nbsp;Volkswagen, with customers noticing a substantial transformation. The vehicle promises a range of up to 279 miles (450 km) and combines the spaciousness of a Golf with the affordability of a Polo.
Why It Matters:&nbsp;Volkswagen&#8217;s push to launch the ID.2 comes amid a challenging period for the company.
In the third quarter of 2024, the automaker experienced a 10% decline in electric vehicle sales, primarily in the U.S. and Europe, although&nbsp;<a href="https://www.benzinga.com/news/24/10/41307960/volkswagen-ev-sales-drop-10-in-q3-due-to-slowdown-in-us-and-eu-but-china-shines-as-a-bright-spot-wit">China showed a 5% growth</a>. This underscores the importance of the ID.2 as a strategic move to capture a larger market share.
Meanwhile, Volkswagen has been making strategic investments, such as increasing its stake in Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>). Analysts see this as a vital step for both companies, aiding in production and cost efficiency. The collaboration is expected to provide <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41938838/rivians-deal-with-volkswagen-will-help-ev-giant-navigate-the-ship-in-stormy-waters-says-top-analyst-maintains-outperform-rating-with-20-target">capital for future growth</a>, enhancing vehicle offerings and software integration.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Volkswagen

RIVN

VWAGY

Volkswagen's Affordable ID.2 EV Set For 2025 Launch, SUV Variant To Follow: 'Stable And Likable With Our Secret Sauce'

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is set to face a multibillion-dollar lawsuit following the <a href="https://www.benzinga.com/general/social-media/24/06/39259832/metas-legal-battle-over-cambridge-analytica-scandal-heads-to-supreme-court">dismissal of its appeal</a> by the U.S. Supreme Court over the Cambridge Analytica data scandal.
What Happened: The Supreme Court, which heard arguments on Meta's appeal on Nov. 6, gave no explanation for the dismissal.&nbsp;
It only stated that the case was being "dismissed as improvidently granted," <a href="https://www.bloomberg.com/news/articles/2024-11-22/facebook-appeal-over-shareholder-suit-dropped-by-supreme-court?srnd=phx-technology">reported</a> Bloomberg.&nbsp;
This dismissal increases the likelihood of Mark Zuckerberg's Meta facing a costly settlement, potentially as large as $2 billion, according to Bloomberg Intelligence analyst Matthew Schettenhelm.
In a statement, Meta has expressed disappointment and maintained that the plaintiff&#8217;s claims are baseless. "We will continue to defend ourselves as this case is considered by the district court."
See Also: <a href="https://www.benzinga.com/24/11/42053396/why-chinese-tech-giants-alibaba-bytedance-and-meituan-are-expanding-their-ai-footprints-in-silicon-valley-amid-us-efforts-to-block-progress?itm_source=parsely-api">China&#8217;s Tech Giants Alibaba, ByteDance, And Meituan Are Expanding Their Silicon Valley AI Footprints Amid US Efforts To Block Progress</a>
Meta is accused of misleading shareholders about the risks associated with the 2018 Cambridge Analytica scandal, involving the unauthorized use of personal data from over 30 million users.
The shareholders argue that revelations about the breach eventually led to two 2018 price drops that cost the company more than $200 billion in market value.
Meta did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for a statement.
Why It Matters: Meta faced another legal setback in October when a U.S. District Judge rejected the company's attempt to dismiss claims made in two separate lawsuits filed by U.S. states.
The lawsuits accused <a href="https://www.benzinga.com/news/24/10/41349398/mark-zuckerbergs-meta-to-face-lawsuits-over-teen-social-media-addiction-judge-rejects-dismissal-moti">Meta of contributing to mental health</a> issues among teenagers by making its platforms addictive.
Moreover, shareholder lawsuits have been a common occurrence in the tech industry. For instance, In October Alibaba Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) agreed to a $433.5 million settlement in a class-action l<a href="https://www.benzinga.com/markets/equities/24/10/41559403/alibaba-agrees-to-433-5m-settlement-in-shareholder-class-action-lawsuit">awsuit filed by its shareholders</a>.
Similarly, Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) also <a href="https://www.benzinga.com/news/legal/24/11/42015978/shareholder-lawsuit-challenges-tilrays-voting-tactics-for-authorized-share-increase">faced a shareholder lawsuit</a> accusing the company of misleading voting practices.
Currently, the Supreme Court is also reviewing an appeal by <a href="https://www.benzinga.com/news/legal/24/11/41960485/nvidias-crypto-past-returns-to-haunt-as-supreme-court-signals-green-light-for-lawsuit">Nvidia Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which faces a lawsuit alleging it <a href="https://www.benzinga.com/news/legal/24/11/41960485/nvidias-crypto-past-returns-to-haunt-as-supreme-court-signals-green-light-for-lawsuit">misled shareholders about</a> its dependence on crypto-mining revenue ahead of a market crash.
Price Action: Meta&#8217;s shares dropped 0.7% on Friday, ending the day at $559.14. In after-hours trading, the stock gained 0.098%, reaching $559.69 as of this writing, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42132292/mark-zuckerbergs-meta-takes-on-64b-pig-butchering-scams-targeting-people-through-dating-apps-social-media-crypto-investing-and-other-apps">Mark Zuckerberg&#8217;s Meta Cracks Down On $64B &#8216;Pig Butchering&#8217; Scams Involving Dating Apps, Social Media And Crypto Investing</a></li>
</ul>
Photo courtesy: Shutterstock

Legal

Media

BABA

NVDA

TLRY

Meta Faces Multibillion-Dollar Lawsuit As Supreme Court Dismisses Appeal In Cambridge Analytica Data Scandal

The Securities and Exchange Commission or SEC has set a new record in financial penalties, with a significant portion resulting <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40809382/terraform-labs-historic-4-5b-settlement-with-sec-makes-2024-the-most-penalized-year-for-cr">from a settlement with</a> Terraform Labs.
What Happened: The regulator has gathered $8.2 billion in monetary penalties for the fiscal year 2024, marking the highest amount in the agency&#8217;s history.
This figure represents a 67% increase from the $4.9 billion collected in fiscal year 2023.
Despite the record penalty collection, the SEC saw a 26% decline in enforcement actions during the year, with 583 actions taken.
The regulator also barred 124 individuals from serving as officers and directors of public companies, marking the second-highest number in a decade.
See Also: <a href="https://www.benzinga.com/news/global/24/11/42148498/wall-street-rebounds-without-its-ai-darlings-boost-king-dollar-maintains-dominance-while-bitcoin-defies-gravity-this-week-in-the-markets?itm_source=parsely-api">Wall Street Rebounds Without Its AI Darling&#8217;s Boost, King Dollar Maintains Dominance While Bitcoin Defies Gravity: This Week In The Markets</a>
Moreover, the SEC returned $345 million to investors who had been impacted, bringing the total amount returned since fiscal year 2021 to over $2.7 billion.
The agency also processed 45,130 tips, complaints, and referrals during the year — a record high — including over 24,000 whistleblower submissions.
Notably, more than 14,000 of those submissions came from just two individuals. The regulator has awarded whistleblowers a total of $255 million.
Why It Matters: The SEC has been cracking down on companies for misleading public disclosures related to cybersecurity risks and breaches.
The record-breaking total was largely influenced by a significant monetary judgment against cryptocurrency company Terraform Labs and its former CEO Do Kwon, following a successful SEC jury trial.
The case was one of the largest securities frauds in U.S. history.
Another notable financial <a href="https://www.benzinga.com/markets/equities/24/01/36649969/morgan-stanley-to-pay-249m-penalty-in-block-trade-case-how-leaks-cost-blackstone-oaktree-million">penalty was a $249 million</a> settlement with Morgan Stanley, resolving SEC charges related to the disclosure of confidential information about large stock sales.
In October, the regulator also <a href="https://www.benzinga.com/government/24/10/41470706/sec-charges-four-companies-over-solarwinds-hacks-issues-millions-in-penalties">charged four major companies</a> over the SolarWinds hacks, issuing millions in penalties.
Earlier this month, JPMorgan Chase &amp; Co. also agreed to <a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">pay investors $151 million</a> following SEC charges for various law violations.
The stringent regulatory approach, particularly towards cryptocurrencies, has been a hallmark of SEC Chair Gary Gensler&#8217;s tenure, who <a href="https://www.benzinga.com/government/regulations/24/11/42120607/gary-gensler-to-step-down-as-sec-chair-on-trumps-inauguration-day">announced that he will step down</a> in January.
During his tenure, the SEC pursued <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40568347/after-binance-and-coinbase-gary-gensler-led-sec-set-to-lock-horns-with-crypto-exchange-kra">several enforcement actions</a> against prominent cryptocurrency firms, including filing lawsuits against Coinbase and Binance for allegedly running unregistered securities exchanges.
In July, President-elect Donald Trump had stated, "I will <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40018935/trumps-bitcoin-conference-pledge-can-he-really-fire-sec-chair-gensler">fire Gary Gensler</a> on day one." His statement was an indication of a possible change in the SEC's stance on digital assets with the new administration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42134031/markets-got-it-wrong-after-elections-prospects-of-tariffs-not-good-for-equities-vs-dollar-says-ex-goldman-sachs-analyst?itm_source=parsely-api">Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: &#8216;Prospects Of Tariffs Not Good For Equities&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SEC Shatters Record With $8.2B In Penalties For 2024, Led by Terraform Labs' Massive Settlement

Eric Jackson, the founder and portfolio manager at EMJ Capital, has shared his thoughts on the potential catalysts that could drive Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) value to $100,000.
What Happened: On Friday, Jackson appeared on CNBC&#8217;s Closing Bell and suggested that the upcoming Thanksgiving holiday, new SEC policies, and global adoption could spark Bitcoin&#8217;s next bull run.
During the interview, Jackson stated, &#8220;I think a lot of people that I talk to say, well, it&#8217;s just going to kiss $100,000 and pull back.&#8221;&nbsp;
Adding, &#8220;But I do think there&#8217;s a chance like that $100,000 milestone could be a rethink for a lot of investors both institutional, sovereign retail, and there are a bunch of catalysts ahead I think.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42052184/will-shiba-inu-coin-reach-1-cent-by-2025-47-of-benzinga-readers-say?itm_source=parsely-api">Will Shiba Inu Coin Reach 1 Cent By 2025? 47% Of Benzinga Readers Say…</a>
He went on to explain that the new SEC regime and the potential for a strategic reserve could be significant catalysts for Bitcoin.
Jackson also said that the Thanksgiving period often acts as a springboard for bullish crypto periods, rather than a setback.
He concluded by saying, &#8220;I think those names, you know, and the fact that they … there&#8217;s a real structure that&#8217;s going to be coming into place, around crypto and Bitcoin, I think those will be catalysts in and of themselves.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> hitting an all-time high again today on the path to $100K. How much longer can the supportive action continue? <a href="https://twitter.com/ericjackson?ref_src=twsrc%5Etfw">@EricJackson</a> discusses:<a href="https://t.co/Z3PZanYx4F">https://t.co/Z3PZanYx4F</a>
&mdash; CNBC&#39;s Closing Bell (@CNBCClosingBell) <a href="https://twitter.com/CNBCClosingBell/status/1860091069284962733?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Earlier, Galaxy Digital Holdings Ltd. CEO Mike Novogratz warned of a potential pullback due to excessive market leverage, but maintained that Bitcoin <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">reaching $100,000 is &#8220;inevitable.&#8221;</a>
Meanwhile, MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman Michael Saylor has predicted that Bitcoin could hit $13 million by 2045, a valuation that would put Bitcoin's market <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116183/michael-saylor-predicted-bitcoin-to-hit-13-million-if-it-happens-it-will-entail-massive-hyperinflation-analyst-warns">cap at around $250 trillion</a>.
Companies like MicroStrategy, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121936/bitcoin-boom-20-microstrategy-gains-traction-as-a-leveraged-bet-on-crypto-growth">owns more than 150,000 Bitcoins</a>, are emerging as key players in this evolving market, effectively operating as a leveraged bet on the cryptocurrency.
In a note to Benzinga, Sumit Gupta, co-founder of CoinDCX, highlighted the surge in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42135905/bitcoin-nears-100000-momentum-could-continue-well-beyond-the-milestone-experts-note">trading activity as a key driver</a>. He also pointed to developments in the U.S. political landscape as a contributing factor.
The digital asset market has already benefited from the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42131449/with-gary-gensler-preparing-to-quit-in-2025-secs-crypto-cases-likely-to-quietly-go-away-amid-trumps-pro-bitcoin-stance-says-pantera-capitals-katrina-paglia">incoming administration</a> of President-elect Donald Trump, with many speculating that a potential second term could bring more favorable regulatory policies for crypto.
Gupta added that speculation over SEC Chair Gary Gensler's resignation and the possibility of crypto-friendly leadership has further fueled investor optimism.
Price Action: At the time of writing, Bitcoin was trading at $98,816, up nearly 0.2% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/education/24/11/42098422/heres-how-much-100-invested-in-cardano-today-could-be-worth-if-ada-hits-new-all-time-highs?itm_source=parsely-api">Here&#8217;s How Much $100 Invested In Cardano Today Could Be Worth If ADA Hits New All-Time Highs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Pixabay

MSTR

Bitcoin's Road To $100K: Why Thanksgiving, New SEC Policies, And Global Adoption Could Spark The Next Bull Run, According To This Portfolio Manager

President-elect Donald Trump has picked hedge fund executive Scott Bessent as the U.S. Treasury Secretary.
What Happened: Bessent, 62 and founder of Key Square Group, was a leading candidate, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42091821/could-donald-trumps-potential-treasury-secretary-be-out-of-his-depth-on-crypto-policy-polymarket-traders-just-cant-decide-on-a-favorite">competing with</a> former Fed Governor Kevin Warsh and private equity executive Marc Rowan.
While sharing the decision on Friday via his social media platform Truth Social, Trump lauded Bessent as "one of the World's foremost International Investors and Geopolitical and Economic Strategists."
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22205557/Screenshot-2024-11-23-at-7.25.49%E2%80%AFAM-900x1024.png" alt="" class="wp-image-661913" /><figcaption class="wp-element-caption">Source: Truth Social</figcaption></figure>
See Also: <a href="https://www.benzinga.com/news/legal/24/11/42147981/trumps-hush-money-sentencing-delayed-as-legal-immunity-debate-escalates">Trump&#8217;s Hush Money Sentencing Delayed As Legal Immunity Debate Escalates</a>
Bessent is known for his support of gradual tariffs and deregulation, aligning with Trump&#8217;s economic vision, which includes reviving manufacturing and achieving energy independence.
Despite his previous role as chief investment officer for George Soros' fund, Trump expressed confidence in Bessent&#8217;s ability to improve U.S. competitiveness and address trade imbalances.
Why It Matters: As Treasury Secretary, Bessent will replace outgoing Secretary Janet Yellen, overseeing financial institutions and combating financial crimes at a time when <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">the national debt has ballooned to $36 trillion</a>.
According to <a href="https://www.benzinga.com/government/regulations/24/11/41909846/trumps-treasury-pick-frontrunner-scott-bessent-could-shift-wall-street-crypto">betting markets</a>, Bessent was a frontrunner with an 82% probability of securing the nomination. His appointment could significantly impact Wall Street and the crypto sector.
In October, Bessent assured that a new Trump administration would <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41308042/trump-adviser-defends-ex-presidents-economic-policies-strong-dollar-would-natural">support a strong dollar</a>, countering previous suggestions of a weaker dollar to boost exports.
Despite Elon Musk&#8217;s support for Howard Lutnick, <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump favored Bessent&#8217;s</a> business-as-usual approach.
In July, Bessent gained attention for his optimistic stance on cryptocurrency, suggesting he might support digital assets if confirmed. &#8220;Crypto is about freedom and the crypto economy is here to stay,&#8221; he stated at the time.
The latest 13F filing from Bessent&#8217;s Key Square Group fund shows a highly concentrated portfolio, with equal investments in two banking-focused ETFs: the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) and the SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>), each making up 50% of the fund.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42146895/are-you-rich-enough-to-benefit-from-trumps-tax-breaks-heres-how-much-youd-need-to-be-part-of-the-top-5">Are You Rich Enough To Benefit From Trump&#8217;s Tax Breaks? Here&#8217;s How Much You&#8217;d Need To Be Part Of The Top 5%</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Government

Regulations

Politics

Economics

Trump Picks Hedge Fund Exec Scott Bessent As Treasury Secretary: What President-Elect's Choice Means For America's Economic Future

APLMW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

APLM

UBS analyst Jay Sole maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Sell and raises the price target from $14 to $16.

Analyst Ratings

UBS Maintains Sell on Gap, Raises Price Target to $16

UBS analyst Mark Carden maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $102 to $108.

UBS Maintains Buy on BJ's Wholesale Club, Raises Price Target to $108

UBS analyst Steven Fisher maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $404 to $462.

UBS Maintains Neutral on Deere, Raises Price Target to $462

UBS analyst Karl Keirstead maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and raises the price target from $275 to $360.

UBS Maintains Neutral on Salesforce, Raises Price Target to $360

Jefferies analyst Lloyd Byrne maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Hold and raises the price target from $12 to $22.

Jefferies Maintains Hold on Bloom Energy, Raises Price Target to $22

Jefferies analyst Jonathan Petersen maintains SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) with a Hold and raises the price target from $70 to $72.

Jefferies Maintains Hold on SL Green Realty, Raises Price Target to $72

Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC").
Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023.
The current notice will have no immediate effect on the listing or trading of Ocean Biomedical's common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company's common stock. On October 16, 2024, Staff notified the Company that since it failed to timely file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024, the Company's securities were subject to delisting. The Company is now delinquent in the filing its form 10-Q for the period ended September 30, 2024. Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the "Panel") will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market, which hearing is scheduled for December 16, 2024. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.

OCEA

Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report

DA Davidson analyst Gil Luria maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Neutral and raises the price target from $60 to $70.

PCOR

DA Davidson Maintains Neutral on Procore Technologies, Raises Price Target to $70

Chesapeake Utilities Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) ("Chesapeake Utilities" or the "Company") today announced that it has established an at-the-market equity offering program (the "ATM Program") under which it may, from time to time, sell shares of its common stock having an aggregate sales price of up to $100,000,000 (the "Shares"). Chesapeake Utilities has entered into an equity distribution agreement with each of RBC Capital Markets, LLC, Barclays Capital Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann &amp; Co. Inc., Guggenheim Securities, LLC, Citizens JMP Securities, LLC, M&amp;T Securities, Inc., Maxim Group LLC, PNC Capital Markets LLC, and Siebert Williams Shank &amp; Co., LLC (collectively, the "Sales Agents"), as sales agents. Pursuant to the equity distribution agreement, sales of the Shares may be made in transactions deemed to be "at-the-market offerings," as defined in Rule 415 under the Securities Act of 1933, as amended, including by sales made directly on or through the New York Stock Exchange. Chesapeake Utilities intends to use the proceeds from the sales, if any, of the Shares for general corporate purposes, including, but not limited to, financing of capital expenditures, repayment of short-term debt, financing acquisitions, investing in subsidiaries, and general working capital purposes.

Offerings

Chesapeake Utilities Corporation Announces $100M At-The-Market Equity Offering Program

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!



Moving stocks this morning are earnings reports, a dividend, shareholder meeting results and more.



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MBIA (NYSE:<a href="https://investorplace.com/stock-quotes/mbi-stock-quote/">MBI</a>) stock is rocketing more than 58% after <a href="https://finance.yahoo.com/news/mbia-inc-declares-extraordinary-cash-213700040.html">declaring a special cash dividend</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are soaring over 55% alongside heavy pre-market trading.</li>



<li>FLJ (NASDAQ:<a href="https://investorplace.com/stock-quotes/flj-stock-quote/">FLJ</a>) stock is surging close to 45% with strong early morning trading.</li>



<li>Torrid (NYSE:<a href="https://investorplace.com/stock-quotes/curv-stock-quote/">CURV</a>) shares are gaining more than 16% after releasing its <a href="https://www.nasdaq.com/press-release/torrid-reports-third-quarter-fiscal-2023-results-2023-12-07">Q3 earnings report</a>.</li>



<li>Meta Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/">MMAT</a>) stock is increasing over 13% as it <a href="https://investorplace.com/2023/12/mmat-stock-meta-materials-speaks-out-on-reverse-stock-split-proposal/">seeks a reverse stock split</a>.</li>



<li>Micromobility.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcom-stock-quote/">MCOM</a>) shares are climbing more than 13% without any clear news.</li>



<li>Biolase (NASDAQ:<a href="https://investorplace.com/stock-quotes/biol-stock-quote/">BIOL</a>) stock is heading over 12% higher after <a href="https://www.nasdaq.com/press-release/biolase-inc.-announces-pricing-of-%241.4-million-registered-direct-offering-priced-at">pricing an offering yesterday</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are rising more than 12% this morning.</li>



<li>Root (NASDAQ:<a href="https://investorplace.com/stock-quotes/root-stock-quote/">ROOT</a>) stock is jumping over 11% without any obvious news on Friday.</li>



<li>Virax Biolabs (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrax-stock-quote/">VRAX</a>) shares are up more than 11% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317915935&amp;type=PDF&amp;symbol=VRAX&amp;cdn=b06fb6b886b911f8cbc436f2eecb3a52&amp;companyName=Virax+Biolabs+Group+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2023-12-08">shareholder meeting results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is plummeting over 36% following <a href="https://investorplace.com/2023/12/why-is-cyngn-cyn-stock-up-73-today/">a major rally yesterday</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares are diving more than 23% as it continues a recent fall.</li>



<li>HashiCorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcp-stock-quote/">HCP</a>) stock is tumbling over 23% with its <a href="https://finance.yahoo.com/news/hashicorp-announces-third-quarter-fiscal-210500073.html">latest earnings release</a>.</li>



<li>Hempacco (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpco-stock-quote/">HPCO</a>) shares are taking a more than 21% beating <a href="https://investorplace.com/2023/12/why-is-hempacco-hpco-stock-up-56-today/">after a rally yesterday</a>.</li>



<li>Troika Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/trka-stock-quote/">TRKA</a>) stock is sliding over 19% after <a href="https://investorplace.com/2023/12/why-is-troika-media-group-trka-stock-down-77-today/">filing for bankruptcy</a>.</li>



<li>Avid Bioservices (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdmo-stock-quote/">CDMO</a>) shares are decreasing more than 19% after <a href="https://finance.yahoo.com/news/avid-bioservices-cdmo-reports-q2-224002715.html">releasing lackluster earnings</a>.</li>



<li>China Liberal Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/cleu-stock-quote/">CLEU</a>) stock is falling over 18% after rallying yesterday.</li>



<li>Save Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/svfd-stock-quote/">SVFD</a>) shares are slipping more than 15% after <a href="https://www.marketwatch.com/story/save-foods-shares-more-than-double-on-nitrousink-deal-9bde44aa">rallying Thursday on a deal</a>.</li>



<li>Greenbrook TMS (NASDAQ:<a href="https://investorplace.com/stock-quotes/gbnh-stock-quote/">GBNH</a>) stock is dipping over 13% today.</li>



<li>Parts ID (NYSEMKT:<a href="https://investorplace.com/stock-quotes/id-stock-quote/">ID</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-dec-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are investments, acquisitions, new agreements and more.



Let&rsquo;s get into that news down



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 71% with heavy trading on Empery Asset Management, LP <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981363&amp;type=PDF&amp;symbol=VLCN&amp;cdn=0a561d788a48501f1c170c0f63b65ac5&amp;companyName=Volcon+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-01-11">taking a stake in the company</a>.</li>



<li>Charge Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/">CRGE</a>) shares are soaring over 41% with strong early morning trading.</li>



<li>Aeries Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/aert-stock-quote/">AERT</a>) stock is surging more than 35% alongside heavy trading this morning.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) shares are increasing over 20% as it also sees strong trading on Friday morning.</li>



<li>Aileron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/">ALRN</a>) stock is gaining more than 18% following its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981539&amp;type=PDF&amp;symbol=ALRN&amp;cdn=2219d39279c110c1197b97762ea29d5d&amp;companyName=Aileron+Therapeutics+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-11">acquisition of Lung Therapeutics</a>.</li>



<li>Hyperfine (NASDAQ:<a href="https://investorplace.com/stock-quotes/hypr-stock-quote/">HYPR</a>) shares are heading over 16% higher without any clear news this morning.</li>



<li>Akso Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/">AHG</a>) stock is climbing more than 14% today.</li>



<li>Emcore (NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/">EMKR</a>) shares are jumping over 13% with a <a href="https://www.nasdaq.com/press-release/emcore-corporation-enters-into-cooperation-agreement-with-bradley-l.-radoff-2024-01">new cooperation agreement</a>.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is rising more than 13% this morning.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) shares are up over 13% on Friday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) stock is crashing more than 46% without any obvious news.</li>



<li>Genius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/">GNS</a>) shares are plummeting over 34% after <a href="https://www.nasdaq.com/press-release/genius-group-announces-pricing-of-%248.25-million-public-offering-2024-01-12">pricing a public offering</a>.</li>



<li>VCI Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcig-stock-quote/">VCIG</a>) stock is diving more than 27% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317975438&amp;type=PDF&amp;symbol=VCIG&amp;cdn=d1e913c93adb43c9620f5e05d59906d8&amp;companyName=VCI+Global+Limited&amp;formType=F-1%2FA&amp;formDescription=%5BAmend%5D+Registration+statement+for+certain+foreign+private+issuers&amp;dateFiled=2024-01-08">a public offering</a>.</li>



<li>SealSQ (NASDAQ:<a href="https://investorplace.com/stock-quotes/laes-stock-quote/">LAES</a>) shares are taking an over 20% beating <a href="https://www.globenewswire.com/news-release/2024/01/10/2807169/0/en/SEALSQ-Announces-FY-2023-Preliminary-Unaudited-Revenue-of-30-Million-Marking-a-29-Increase-Over-FY-2022.html">alongside preliminary earnings</a>.</li>



<li>Future FinTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/ftft-stock-quote/">FTFT</a>) stock is tumbling more than 13% following <a href="https://www.marketwatch.com/story/future-fintech-stock-drops-13-after-sec-charges-ceo-68d81977">charges against its CEO</a>.</li>



<li>Vivopower (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) shares are sliding over 12% after its <a href="https://www.marketwatch.com/story/vivopower-international-shares-rise-after-subsidiary-tembo-meets-milestones-for-strategic-direct-equity-investment-05502abe">subsidiary met certain milestones</a>.</li>



<li>Tarena International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock is decreasing more than 11% this morning.</li>



<li>MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) shares are dropping over 11% on Friday.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling more than 9% without any news to report.</li>



<li>Eightco (NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/">OCTO</a>) shares close out our pre-market stock movers down close to 9%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> that will provide high returns this year, with their new advances.



<h2>Catalyst Pharmaceuticals (CPRX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>


Catalyst Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/">CPRX</a>) is a pharmaceutical company that focuses on licensing the rights to the cures of rare diseases. It has a valuation of $<a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX">14.36</a>, with a YoY decrease of <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX&amp;window=1Y">28.70%</a>. However, it appears to be poised for growth.



Although Catalyst has consistently <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">missed earnings estimates</a> by small margins, 4 Yahoo Finance! investors have given it a <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">buy rating</a>. Additionally, 5 analysts have given it a price target of <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">$26.20</a>, far above its current valuation. It has a debt of $3.64 million, with a free cash flow of $120.97 million. This gives it plenty of liquid assets to invest in the development of new drugs.



A few key drugs Catalyst has in its pipeline include drugs for <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer">Duchenne muscular dystrophy</a>. This disease will have a market of <a href="https://www.alliedmarketresearch.com/duchenne-muscular-dystrophy-market-A15646">$2.07 billion in 2031</a>, with a CAGR of 4.7%. This is much more than Catalyst&rsquo;s current market cap of <a href="https://finance.yahoo.com/quote/CPRX/key-statistics?p=CPRX">$1.69 billion</a>, showing potential for future growth. Additionally, sales for current drugs are expected to hold steady. This makes it one of those biotech stocks to consider.



Management is expected to continue buying the rights to and developing drugs for niche, in-demand disorders. This opens the possibility of future growth. Coupled with being perceived as undervalued at the moment, it becomes clear why Catalyst Pharmaceuticals is a stock you should invest in.



<h2>Estrella Immunopharma (ESLA)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>


Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) is an American biopharmaceutical company focusing on the development of T-cell therapies. Headquartered in Emeryville, CA, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$1.03</a>.&nbsp;



Developing innovative therapies for solid tumors using novel &ldquo;mark-and-kill&rdquo; methods, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$62.67</a> &mdash; down 14.17% in the past month.



Valued at <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$36.26 millio</a>n, the biopharmaceuticals market size is estimated at $516.79 billion in 2024 and is expected to reach $761.80 billion by 2029, growing at a <a href="https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry">CAGR </a>of 8.07% during the forecast period.



Financially, ESLA improved on almost every metric during Q3 2023. ESLA reported <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$-1.87 million</a> in net income, a YoY increase of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">35.17%</a>. Total assets also received a massive surge of $27.35 million increasing over<a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX"> 750%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for ESLA, with the company outperforming previous years on net change in cash, increasing 1,886.80% YoY. This increase in liquidity makes it one of those biotech stocks for investors to pay close attention to.



ESLA is set up for success through recent <a href="https://www.estrellabio.com/pipeline">research</a> in novel drugs and therapies. It is developing advanced T-cell therapies, particularly focusing on its CD19-Redirected ARTEMIS T Cells. This approach is being applied initially to high-risk blood cancers. As ESLA continues to include an emphasis on research and development, expect ESLA valuation to climb as more customers gravitate towards the company&rsquo;s products.



<h2>VolitionRX (VNRX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


VolitionRX (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/">VNRX</a>) is a biotech company that takes part in the creation of blood-based cancer tests, helping diagnose a range of cancers. The company is based in Henderson, NV, and has amassed a valuation of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$0.86</a> with a strong increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">48.88%</a> in just the last month.&nbsp;&nbsp;



VNRX is fully established in the market but still shows signs of future growth. Valued at <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$67.94 million</a> in 2023, The global biotechnology market size accounted for $368 Billion in 2021 and is anticipated to reach $1,334 Billion by 2030 with a <a href="https://www.linkedin.com/pulse/biotechnology-market-anticipated-reach-usd-1334-billion/">CAGR </a>of 15.5%. 



Financially, VNRX improved on almost every metric during Q3 2023. VNRX reported <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$165.21K</a> in revenue, a YoY increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">405.02%</a>. Net profit margin also received massive surges of $-5.07K, increasing over <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">70%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for VNRX, with the company YoY outperforming EPS by 23.64%.&nbsp;



VNRX is set up for success through recent<a href="https://finance.yahoo.com/news/volition-vpg-launch-nu-q-112400172.html"> announcements</a> of closing on an aggregate of $5.5 m<a href="https://finance.yahoo.com/news/volitionrx-secures-approximately-5-5-130000482.html">illion</a> in financing from investors at Wallonie Entreprendre in Belgium. It has also recently partnered with leading laboratories in the UK and Ireland to launch a groundbreaking cancer test for the early detection and monitoring of cancer in dogs. As VNRX continues to include an emphasis on innovation, expect VNRX valuation to climb as more investors and clients gravitate towards the company&rsquo;s services.



On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



The researchers contributing to this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/01/next-big-thing-3-biotech-stocks-to-watch-for-groundbreaking-advances/">Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Estrella Immunopharma (ESLA) has shared an update. Estrella Immunopharma, Inc. has recently updated their investor presentation on their website, w...

Estrella Immunopharma Unveils Updated Investor Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) just reported results for the third quarter of 2024.<ul><li>Estrella Immunopharma reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/esla-stock-earnings-estrella-immunopharma-for-q3-of-2024/">ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The latest announcement is out from Estrella Immunopharma (ESLA). Estrella Immunopharma, Inc. has appointed Ms. Hong Zhang as the new Chairperson a...

Estrella Immunopharma Welcomes New Chairperson, Expands Board

Estrella Immunopharma ( ($ESLA) ) just unveiled an update. Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO ...

Comments

Estrella Immunopharma

Estrella Immunopharma (ESLA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL